The Correlation Between Idiopathic Pulmonary Fibrosis and Lung Cancer

Yuming Liu

doi:10.62051/ybhfac94

Authors

Yuming Liu

DOI:

https://doi.org/10.62051/ybhfac94

Keywords:

lung cancer; idiopathic pulmonary fibrosis; relationship.

Abstract

The prevalent chronic lung condition known as idiopathic pulmonary fibrosis (IPF) is defined with the repeated scarring of pulmonary tissues. About 3 million individuals are impacted globally, and that figure is only increasing. There are no effective treatments available right now to help IPF sufferers with their symptoms. The lungs, one of the essential organs in charge of exchanging oxygen, are affected by lung cancer, a terrible condition that can be fatal. It affects both men and women of all ages and is the main reason for cancer-related deaths globally. This research focuses on the correlation between similar risk factors and related causes of these two diseases. By discussing the transforming growth factor β (TGF-β) and telomeres, it would be able to see how the two diseases are related. In addition, targets for the vaccination will also be analyzed, and the current stages of clinical therapeutic methods will be discussed.

Downloads

Download data is not yet available.

References

Urteaga M, Ruz J, González M. Idiopathic pulmonary fibrosis. Radiología, 2022, 64: 227 - 239.

Wolters P, Collard H, Jones K. Pathogenesis of idiopathic pulmonary fibrosis. Annual Review of Pathology: Mechanisms of Disease, 2014, 9: 157 - 179.

Zhang Q, Yu N, Lee C. Mysteries of TGF-β paradox in benign and malignant cells. Frontiers in oncology, 2014, 4: 94.

Armanios M, Chen J, Cogan J, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. New England Journal of Medicine, 2007, 356 (13): 1317 - 1326.

Alder J K, Chen J J L, Lancaster L, et al. short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proceedings of the National Academy of Sciences, 2008, 105 (35): 13051 - 13056.

Trachtman H, Fervenza F C, Gipson D S, et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney international, 2011, 79 (11): 1236 - 1243.

Peng D, Fu M, Wang M, et al. Targeting TGF-β signal transduction for fibrosis and cancer therapy. Molecular cancer, 2022, 21 (1): 104.

Chung J, Chan M, Li J, et al. TGF-β signaling: from tissue fibrosis to tumor microenvironment. International Journal of Molecular Sciences, 2021, 22 (14): 7575.

Mallikarjuna P, Zhou Y, Landström M. The Synergistic Cooperation between TGF-β and hypoxia in Cancer and fibrosis. Biomolecules, 2022, 12 (5): 635.

Huang C, Chung C, Hu T, et al. Recent progress in TGF-β inhibitors for cancer therapy. Biomedicine & Pharmacotherapy, 2021, 134: 111046.